Trailing-twelve-month (TTM) revenue is $4.45 Million with a year-over-year growth of (16.17%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-08-31 | $1,380,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-14 |
| Q2 FY2026Period ended 2025-11-30 | $1,210,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-01-14 |
| Q3 FY2026Period ended 2026-02-28 | $987,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-13 |
| Q4 FY2026Period ended 2026-05-31 | $875,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-31 |
| TTM revenue | $4,452,000 |
Current P/S: $6,228,437 market capitalization ÷ $4,452,000 TTM revenue = 1.40x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:14:20.000Z. Latest revenue period ended 2026-05-31.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-05-31): $875000.00.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:16:01.989Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2021-05-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-05-31 · USD | FY20212021-05-31 · USD |
|---|---|---|
| ClinicalLabMember | $3M | $3M |
| ContractManufacturingMember | $305,760 | $552,000 |
| LabSuppliesMember | N/A | $3,000 |
| OTCMember | $1M | N/A |
| OverthecounterMember | N/A | $766,000 |
| PhysiciansOfficeMember |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-05-31 · USD |
|---|---|
| Asia | $2M |
| Europe | $1M |
| Middle East | $630,000 |
| North America | $2M |
| South America | $8,000 |
$4.45M
$4.45 Million
(16.17%)
vs. $5.31M a year ago (TTM)
(9.17%)
5 Year compound annual growth rate
1 Year
(16.17%)
3 Year
(5.88%)
5 Year
(9.17%)
10 Year
(1.43%)
15 Year
(0.64%)
20 Year
(2.36%)
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $4.45M | ($858,000) | (16.16%) |
| 2025 | $5.31M | ($104,000) | (1.92%) |
| 2024 | $5.42M | +$76,000 | +1.42% |
| 2023 | $5.34M | ($13.53M) | (71.71%) |
| 2022 | $18.87M | +$11.67M | +162.14% |
| 2021 |
TTM Growth
(16.17%)
3-Year CAGR
(5.88%)
5-Year CAGR
(9.17%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:16:01.989Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-05-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2M |
| $3M |
| $7.20M |
| +$506,316 |
| +7.57% |
| 2020 | $6.69M | +$1.49M | +28.69% |
| 2019 | $5.20M | ($363,503) | (6.53%) |
| 2018 | $5.56M | ($227,485) | (3.93%) |
| 2017 | $5.79M | +$651,854 | +12.68% |
